Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

176
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
176
Cancer Vaccines01:30

Cancer Vaccines

514
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
514
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

345
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
345
Vaccinations01:51

Vaccinations

45.3K
Overview
45.3K
Drug Discovery: Overview01:26

Drug Discovery: Overview

8.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness of CoronaVac in a pioneer risk-based allocation clinical trial during the COVID-19 pandemic.

PloS one·2026
Same author

Refining the regulatory and ethics context of controlled human infection models - a stakeholder meeting report.

Biologicals : journal of the International Association of Biological Standardization·2026
Same author

Phase III Probability of Success When Early Development Is Based on a Putative Surrogate Endpoint: A Vaccine Efficacy Case Study.

Pharmaceutical statistics·2026
Same author

Evaluation of the Biological Standardization of Native Der p 1, Der p 2 and Der p 23 Proteins Isolated from Natural Allergen Source.

International journal of molecular sciences·2026
Same author

Indirect protection and long-term effectiveness of inactivated COVID-19 vaccine: a stepped-wedge randomised trial in Serrana, Brazil.

Scientific reports·2026
Same author

Utility of the Ribosomal Gene 18S rRNA in the Classification of the Main House Dust Mites Involved in Hypersensitivity.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Sep 13, 2025

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

1.3K

De-risking vaccine development: lessons, challenges, and prospects.

Vega Masignani1,2, Ricardo Palacios3, Marie-Thérèse Martin4

  • 1GSK, Siena, Italy.

NPJ Vaccines
|July 30, 2025
PubMed
Summary

Developing new vaccines is difficult and expensive. Implementing early de-risking strategies can improve vaccine success rates and ensure sustainable access to vital immunizations for public health.

More Related Videos

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.4K
Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

8.8K

Related Experiment Videos

Last Updated: Sep 13, 2025

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

1.3K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.4K
Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

8.8K

Area of Science:

  • Vaccinology
  • Public Health
  • Pharmaceutical Development

Background:

  • Vaccine development is a lengthy and resource-intensive process.
  • Numerous technical, clinical, regulatory, and manufacturing risks impede progress, particularly for less commercially viable vaccine targets.
  • These challenges have significant public health consequences, limiting the availability of essential vaccines.

Purpose of the Study:

  • To propose strategies for early de-risking in vaccine development.
  • To address the vaccine productivity gap and promote sustainable vaccine access.
  • To enhance the success rates of vaccine development programs through efficient decision-making.

Main Methods:

  • Review of existing challenges in vaccine development.
  • Identification of key risk factors throughout the development lifecycle.
  • Proposal of early-stage decision-making frameworks and strategies.
  • Illustration with practical examples of successful de-risking initiatives.

Main Results:

  • Early and efficient decision-making can mitigate technical, clinical, regulatory, and manufacturing risks.
  • De-risking strategies can improve the economic viability of developing vaccines for challenging targets.
  • Successful implementation of these strategies can lead to increased vaccine program success rates.

Conclusions:

  • Implementing early de-risking strategies is crucial for overcoming hurdles in vaccine development.
  • These strategies can help close the vaccine productivity gap, ensuring broader access to immunizations.
  • Proactive risk management enhances the likelihood of successful vaccine programs and strengthens global public health